Evidence against a major role of adenosine in oxygen-dependent regulation of erythropoietin in rats.
This in vivo study investigated whether adenosine (ADO) plays a role in oxygen-dependent production of erythropoietin (EPO). Exposure of rats to 0.075% carbon monoxide (CO) for four hours was used as a stimulus for EPO production. To inhibit potential effects of ADO, rats were treated with the non-specific ADO antagonist theophylline, the selective ADO A1 receptor blockers DPCPX and KW-3902, the selective ADO A2 receptor blocker DMPX, and AOPCP, an inhibitor of 5'-ectonucleotidase, an ADO generating enzyme that is expressed on the surface of EPO producing cells. To stimulate ADO receptor activity, animals were treated with the selective ADO A1 and A2 receptor agonists CHA and CGS 21680, the ADO reuptake inhibitors dipyridamole and soluflazine and the ADO desaminase inhibitor EHNA. At doses known to interfere with ADO signal transmission in vivo, none of these substances either influenced EPO serum levels in normoxic rats or affected the approximately 30-fold rise in EPO serum levels and the increase in renal EPO mRNA after exposure to carbon monoxide. Continuous administration of theophylline to normoxic rats for seven days did not alter hematocrit, hemoglobin or EPO serum levels. Taken together, these experiments do not support the hypothesis that ADO plays an important role in the regulation of EPO production.
Gleiter
C H
CH
Abteilung Klinische Pharmakologie, Georg-August-Universität, Göttingen, Germany. Gleiter@med.uni-goettingen.de
Brause
M
M
Delabar
U
U
Zebski
H
H
Eckardt
K U
KU
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology*; D000244:Adenosine Diphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D002248:Carbon Monoxide; D004176:Dipyridamole / Q000494:pharmacology; D004232:Diuretics / Q000494:pharmacology; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004921:Erythropoietin / Q000235:genetics / Q000378:metabolism*; D015870:Gene Expression / Q000187:drug effects; D000860:Hypoxia / Q000139:chemically induced / Q000378:metabolism; D007668:Kidney / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D010100:Oxygen / Q000378:metabolism*; D010627:Phenethylamines / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D018047:Receptors, Purinergic P1 / Q000378:metabolism; D013806:Theophylline / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology
D000959:Antihypertensive Agents; D004232:Diuretics; D004791:Enzyme Inhibitors; D010627:Phenethylamines; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D012333:RNA, Messenger; D018047:Receptors, Purinergic P1; D014665:Vasodilator Agents; D014970:Xanthines; C523965:alpha,beta-methyleneadenosine 5'-diphosphate; D004921:Erythropoietin; C054695:soluflazine; C061282:2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; C010192:9-(2-hydroxy-3-nonyl)adenine; D000244:Adenosine Diphosphate; D004176:Dipyridamole; C073525:rolofylline; D002248:Carbon Monoxide; C051360:1,3-dipropyl-8-cyclopentylxanthine; D013806:Theophylline; D000225:Adenine; D000241:Adenosine; D010100:Oxygen